Introduction
============

Atherosclerotic cardiovascular disease is a chronic inflammatory condition that frequently occurs in the aging population.^[@b1-1052020]^ Current understanding is that upon rupture or erosion of an atherosclerotic plaque, a thrombus is formed of aggregated platelets and fibrin which can become vaso-occlusive.^[@b2-1052020]^ Furthermore, platelets contribute to ensuing thrombo-inflammatory reactions through their multiple interactions with vascular cells, leukocytes and the coagulation system, thereby promoting disease progression.^[@b3-1052020]^

Platelets are formed from megakaryocytes in the bone marrow (BM) through a differentiation and maturation process known as megakaryopoiesis. Several transcription factors have been identified over the years that regulate megakaryopoiesis and platelet production, and understanding of key transcriptional regulators is still expanding. Mutations in genes encoding for these transcription factors, along with epigenetic regulators, are accompanied with quantitative and/or qualitative platelet abnormalities, causing thrombo-hemorrhagic complications.^[@b4-1052020]^ Multiple growth factors control megakaryopoiesis and platelet production, of which thrombopoietin and its binding to the thrombopoietin receptor plays a primary role.^[@b5-1052020]^ Megakaryocytes undergo endomitosis to become polyploid and during maturation extensive reorganization of cytoskeletal proteins is required for proplatelet formation and the budding of platelets.^[@b6-1052020]^

A number of recent studies stipulate that the incidence of cardiovascular disease (CVD), such as coronary artery disease, heart failure and ischemic stroke, is higher in patients with so-called somatic driver mutations in hematopoietic stem or progenitor cells, resulting in a clonal expansion of a subpopulation of blood cells.^[@b1-1052020]^ This process, referred to as clonal hematopoiesis of indeterminate potential (CHIP), was proposed to define individuals with somatic clonal mutations in genes related to hematologic malignancies with variant allele fractions of \>2%, but without a known hematologic malignancy or other clonal disorder.^[@b7-1052020]^ This premalignant state is considered to be relatively frequent in the elderly population, where somatic mutations accumulate in a variety of genes controlling hematopoietic stem cell maintenance, expansion and survival. Although CHIP increases the risk of developing hematologic cancer, mostly myeloid neoplasms, the absolute risk is still small. Several excellent recent reviews describe in detail the etiology of clonal hematopoiesis and its relation with CVD.^[@b1-1052020],[@b8-1052020],[@b9-1052020]^ So far, attention has mainly been focused on proposed mechanisms of accelerated inflammation-driven atherosclerosis and increased thrombosis risk through altered function of innate immune cells.

In the present paper, we took a different approach. We confined our search to the current evidence on CHIP mutations that are directly or indirectly linked to qualitative or quantitative platelet traits. Starting from the Online Mendelian Inheritance in Man (OMIM) database complemented with recent literature, we selected and discussed genes that were linked to clonal hematopoiesis as well as to the platelet traits count and function. Since CHIP mutations appeared not to be only associated with increased platelet count and/or function, but also with decreases in these platelet traits, its potential relation to both (athero)thrombotic and hemostatic disorders is presented in this review.

Section 1: Clonal mutations in genes associated with increased platelet count and/or function
=============================================================================================

For several genes encoding for transcription regulators (*ASXL1*), epigenetic regulators (*DNMT3A*, *IDH2*) and cell signaling proteins (*ABL1*, *BCR*, *BRAF*, *JAK2*, *SH2B3*), clonal mutations are known that enhance platelet production, which can be accompanied by enhanced platelet functionality. Related effects are described for several genes with divergent roles (*ABCB6*, *SF3B1*) ([Table 1](#t1-1052020){ref-type="table"} and [Figure 1](#f1-1052020){ref-type="fig"}).
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Relevant genes in clonal hematopoiesis with effects on platelet traits and disease.
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![Clonal hematopoiesis of indeterminate potential (CHIP)-related genes affecting platelet traits and the risk of thrombosis or bleeding. Mutations in genes associated with a thrombotic or bleeding risk are indicated in red and blue, respectively. For genes indicated in black, no such associations are known yet.](1052020.fig1){#f1-1052020}

ABCB6
-----

Multiple so-called ABC transporters play a role in lipid trafficking, and thus may contribute to atherosclerosis. However, the *ABCB6* gene product (A*TP binding cassette subfamily B member 6*) facilitates the ATP-dependent import of porphyrins and heme into mitochondria.^[@b10-1052020]^ Markedly, germline mutations of *ABCB6* are associated with several disease phenotypes, including dyschromatosis, microphthalmia and pseudo-hyperkalemia.

The gene *ABCB6* is highly expressed in BM megakaryocyte progenitor cells and megakaryocytes, but only moderately in platelets. Evidence regarding CVD mainly comes from animal studies. In mice, deficiency in *Abcb6* increased megakaryopoiesis and thrombopoiesis, resulting in an increased platelet count and larger platelet volume, effects that were explained by higher oxidative stress in the presence of accumulating porphyrins.^[@b11-1052020]^ The platelets produced in these mice were hyper-reactive and furthermore, against a high-lipid background, attracted leukocytes, thus enhancing atherosclerosis.^[@b10-1052020],[@b11-1052020]^

In patients with acute promyelocytic or myeloid leukemia, RNA expression levels of *ABCB6* are reduced, suggesting the occurrence of also acquired clonal mutations in this gene.^[@b12-1052020]^ However, so far no strong association with CHIP has been found.^[@b8-1052020]^

ASXL1
-----

The transcriptional regulator *Additional sex combs like 1* (ASXL1) is a chromatin-binding protein, which acts as tumor suppressor and is implicated in the maintenance of normal hematopoiesis. Somatic mutations of this gene are found in patients with a variety of myeloid malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasm (MPN).^[@b13-1052020]^ In particular, mutations in *ASXL1* are detected in 10% of MDS patients and 40% of CMML patients.^[@b14-1052020]^ Hence, this gene is considered as a driver of leukemia and myelodysplasia. The majority of (somatic) mutations provoke a truncation of the C-terminus of the protein, resulting in a loss of transcription regulation. In addition, the truncated form can interact with other proteins to modulate cell proliferation.^[@b15-1052020]^ In mouse models, transgenic expression of a C-terminal truncated Asxl1 mutant resulted in age-dependent anemia, thrombocytosis, and morphological dysplasia.^[@b13-1052020]^ A similar type of thrombocytosis is seen in MDS-refractory anemia patients, carrying *ASXL1* mutations.^[@b13-1052020]^ The prevalence of acquired hematopoietic mutations in *ASXL1* in a healthy population of 60-69 years of age was estimated at 1.5%, and was associated with twice the risk of developing CVD.^[@b16-1052020]^

*BCR* and *ABL1*
----------------

The somatic gene effects of *Breakpoint cluster region protein* (BCR) and *Abelson murine leukemia viral oncogene homolog 1* (ABL1) are highly related, if only because the two proteins share signaling pathways. The proto-oncogene *ABL1* contains an auto-inhibitory SH3 domain which, when deleted, turns it into an oncogene. During a somatic reciprocal translocation of chromosomes 22 and 9, both genes can fuse together. The encoded BCR-ABL1 fusion protein is frequently detected in patients with chronic myeloid leukemia (CML) (90%) or acute lymphoblastic leukemia (ALL) (30%).^[@b17-1052020]^ While CML patients mostly carry the 210 amino-acid variant of BCR-ABL, in ALL patients also a shorter 185 amino-acid variant is present. Both fusion forms display constitutive protein tyrosine kinase activity.^[@b17-1052020]^

The current understanding is that aberrant roles of BCR and ABL1 in hematopoiesis are a consequence of fusion formation, although the main evidence comes from case studies. A fusion variant has been described, which is associated with an increased platelet count, although the mechanism is still unclear.^[@b18-1052020]^ In the few healthy adults carrying a BCR-ABL1 fusion mutation hematopoietic malignancies were not detected. On the other hand, BCR-ABL1 fusions can be considered as indicators for a premalignant state, while the absolute risk of developing CVD is smaller than for the *JAK2* V617F mutation.^[@b19-1052020]^

BRAF
----

The serine-threonine protein kinase BRAF is an essential partner in the mitogenic RAS/RAF/MEK/ERK signaling pathway. The *BRAF* proto-oncogene is expressed in all tissues, where it controls cell proliferation, apoptosis, and differentiation. In addition, BRAF is necessary for embryonic development, as *Braf*-deficient embryos die because of disturbed blood vessel formation.^[@b20-1052020]^

Evidence on the role of BRAF in normal megakaryopoiesis comes from work mainly with immortalized human megakaryoblastic cell lines. Upon stimulation with thrombopoietin, differentiation and proliferation of the cells appeared to rely on BRAF-mediated signaling to ERK.^[@b21-1052020]^ Downregulation of BRAF thus lowered the number of megakaryocytic lineage cells, a phenomenon that was confirmed *in vivo* in chimeric mice.^[@b20-1052020]^

In the Noonan, LEOPARD and cardiofaciocutaneous syndromes, patients carry germline mutations in *BRAF* in regions distinct from those of somatic cancerous mutations. However, only limited changes in BRAF signaling are reported.^[@b22-1052020]^ On the other hand, somatic gain-of-function mutations in the *BRAF* gene accumulate in patients with AML, malignant lymphomas or solid cancers.^[@b23-1052020]^ Next to more common point mutations, rare chromosomal translocations are described for this gene.^[@b24-1052020]^

A frequently observed gain-of-function mutation (V600E) is the driver mutation present in different cancers, including melanomas, solid cancers and hairy cell leukemia (HCL). Patients who suffer from HCL have low blood cell counts, likely due to BM aberrations and splenomegaly.^[@b25-1052020]^ Whether megakaryopoiesis is altered due to a constitutively increased MEK/ERK signaling *via* BRAF still needs to be confirmed.

DNMT3A
------

Clonal mutations of three genes (*DNMT3A*, *IDH2*, *TET2*) have been reported which, directly or indirectly, affect histone methylation and hence these can be considered as epigenetic regulators.

The gene *DNA methyltransferase 3*α (*DNMT3A*) encodes for a DNA methylation enzyme that regulates gene imprinting, chromosome inactivation and tumor suppression. Genetic mutations in the *DNMT3A* gene occur in the rare Tatton-Brown-Rahman syndrome which, as far as is known, is not accompanied by hematopoietic aberrations.

In several acquired blood cancers, but especially in adults with AML, somatic mutations in *DNMT3A* have been reported.^[@b26-1052020]^ About a quarter of all AML patients with *de novo* disease carry variant forms of this protein, most commonly with R882H mutation. The loss-of protein-function in those patients resulted in chromosomal islands of hypomethylation.^[@b27-1052020]^ The same mutation, albeit less frequent, can occur in patients with CMML, MDS or MPN.^[@b26-1052020]^ It is considered that *DNMT3A* mutations in hematopoietic stem cells lead to a pre-leukemic state, waiting for additional mutations to induce leukemia. The time interval from first appearance of the mutation to disease is, however, unclear.^[@b26-1052020]^

In agreement with its relevance for clonal hematopoiesis, a recent report points to an increased incidence of acquired *DNMT3A* mutations in the elderly, with a prevalence of about 15% at 60-69 years of age.^[@b1-1052020]^ Combined with a *JAK2 V*617F mutation (see below), the mutated *DNMT3A* gene associates with essential thrombocythemia (ET) and polycythemia vera (PV).^[@b26-1052020]^ Current understanding is that first acquisition of a *DNMT3A* mutation followed by *JAK2* will result in an ET phenotype. On the other hand, first appearance of the *JAK2* mutation may result in a PV phenotype.^[@b26-1052020]^ Overall, *DNMT3A* mutations in AML patients are associated with higher platelet counts than patients with WT-*DNMT3A*; however, the absolute count is still low (\<150×10^9^/L).^[@b28-1052020]^

Regarding atherosclerosis development and atherothrombosis, studies report increased inflammation, linked to mutated *DNMT3A*, possibly due to a higher production of cytokines.^[@b29-1052020]^ Indeed, in patients carrying an acquired mutation of *DNMT3A*, the risk of CVD appears to be doubled.^[@b1-1052020]^ The higher platelet count observed in AML patients with *DNMT3A* mutations likely occurs secondary to the pro-inflammatory phenotype. So far, no mechanism has been found to link *DNMT3A* mutations directly to platelet traits.

IDH2
----

The enzyme *isocitrate dehydrogenase NADP^+^ 2* (IDH2) localized in mitochondria generates NADPH from NADP^+^, whilst catalyzing the oxidative decarboxylation of isocitrate, ultimately producing D-2-hydroxy-glutarate. By producing NADPH, IDH2 regulates the mitochondrial redox balance, hence mitigating cellular oxidative damage.^[@b30-1052020]^ As expected, genetic mutations in *IDH2* are described to be associated with metabolic diseases. On the other hand, somatic mutations of *IDH2* are found in several cancers, including hematologic malignancies, sarcomas and colon cancer. This is compatible with a role of IDH2 as epigenetic regulator, although the direct evidence for epigenetic effects is still indirect.

The most frequent clonal mutations in *IDH2*, identified in patients with *de novo* AML, concern the protein arginine residues R140Q and R172K. These variants cause a gain-of-function resulting in an abnormal, damaging production of D-2-hydroxyglutaric acid, leading to a hypermethylated state of DNA and histones.^[@b30-1052020]^ In comparison to non-carriers, AML patients carrying the somatic *IDH2* mutations showed a higher platelet count, although the absolute platelet count was still low (\<150×10^9^/L).^[@b31-1052020]^ The same trend for platelet count has also been found in MDS patients.^[@b32-1052020]^ Next to this, in primary myelofibrosis, *IDH* mutations can form a risk factor for leukemic transformation.^[@b33-1052020]^ No association with thrombotic events is known for these patient groups, but bleeding was more common in mutant-carrying patients. In the elderly, the percentage of individuals with clonal hemostasis driver mutations in *IDH2* appeared to be rather low at around 1%.^[@b16-1052020]^ Together, this suggests only mild effects of somatic changes in this gene on clonal hematopoiesis, associated with a slight increase in platelet count by a so far unknown mechanism and an increased bleeding tendency.

JAK2
----

The non-receptor tyrosine kinase *Janus kinase 2* (JAK2) is one of the general regulators of cell survival and proliferation, by controlling, for example, cytokine receptor signaling pathways. Also in hematopoiesis, JAK2 controls precursor cell maintenance and function.^[@b34-1052020]^ Inherited mutations of *JAK2* are detected in patients with hereditary thrombocytosis,^[@b35-1052020]^ while somatic mutations of the gene link to various phenotypes including erythrocytosis.

A well-known acquired *JAK2* variant is the mutation V617F, which is carried by the majority of patients with MPN, i.e. in nearly all PV patients and half of patients with ET or primary myelofibrosis. In general, the V617F mutation affects the proliferation of myeloid cells and leads to increased inflammatory responses.^[@b34-1052020]^ However, this somatic mutation as such is not considered to enhance the risk of thrombotic events in patients with ET or PV.^[@b36-1052020]^ Nevertheless, platelets from *JAK2* V617F-positive patients demonstrated an enhanced activation status and procoagulant potential. In addition, the fraction of immature platelets, which can be more active than mature platelets, was higher in carriers of the *JAK2* V617F mutation versus non-carriers.^[@b37-1052020]^

Transgenic mice have been generated carrying the human *JAK2* V617F mutation in the megakaryocyte lineage.^[@b38-1052020]^ The *JAK2* V617F megakaryocytes responded better to thrombopoietin, and displayed a greater migratory ability, proplatelet formation and increased ploidy. The produced platelets responded stronger to multiple agonists.

In aging healthy individuals, the prevalence of the *JAK2* V617F variant is only 1%, but carriers have a 10-fold increased risk of CVD.^[@b16-1052020]^ Depending on the degree of mutation expansion, subjects may develop MPN instead of CHIP.^[@b8-1052020]^ How or under which conditions the thrombocytosis is linked to somatic *JAK2* mutations aggravating CVD is still a matter of debate and requires further investigation.

SF3B1
-----

The gene *splicing factor 3B subunit 1* (*SF3B1*) encodes for a core component of the RNA spliceosome machinery.^[@b39-1052020]^ Somatic mutations in this gene, along with other genes of the spliceosome, have been identified in over half of MDS patients.^[@b39-1052020]^ Common mutations in the *SF3B1* gene are those of K700E, K666N and R625C.^[@b40-1052020]^ To study the impact of the frequent K300E mutation, a conditional knock-in mouse model was developed, which revealed a RNA splicing defect similar as suggested in MDS patients harboring this mutation.^[@b39-1052020]^ Regarding the thrombotic risk, studies revealed that patients carrying a mutated *SF3B1* gene had higher platelet counts and were more prone to develop CVD than patients without mutation,^[@b40-1052020]^ although the altered molecular players are unclear. Furthermore, a sequencing study identified *SF3B1* mutations in 5% of ET patients.^[@b41-1052020]^ In the aging healthy population, clonal hematopoietic mutations of *SF3B1* appear to be infrequent, ranging from 2 to 5%.^[@b42-1052020]^

SH2B3
-----

The signaling adaptor protein *Src homology 2 B3* (SH2B3, also named LNK) acts as an interactor of JAK2, and negatively regulates thrombopoietin-induced megakaryopoiesis. An associated inherited disease is B-precursor acute lymphoblastic leukemia. Somatic mutations in the *SH2B3* gene are found in \>5% of MPN patients. These concern frameshift and missense mutations throughout the whole gene, often co-existing with mutations in driver genes, including *JAK2*, *CALR* and *MPL*.^[@b43-1052020]^ The loss-of-function of SH2B3 can lead to a higher expansion of hematopoietic stem cells, acting by increased thrombopoietin signaling and megakaryopoiesis.^[@b44-1052020]^ The higher platelet and leukocyte counts may worsen atherosclerosis and the thrombotic risk.^[@b43-1052020]^ In *Sh2b3* knockout mice, it was found that hyperlipidemia aggravated both atherosclerosis and thrombosis, likely due to positive platelet priming.^[@b45-1052020]^ Whether this priming event due to *SH2B3* mutations also occurs in humans, is not known.

Section 2: Clonal mutations in genes associated with decreased platelet count and/or function
=============================================================================================

Several mutations in genes encoding for transcription regulators (*ETV6*, *GATA2*, *GFI1B*, *SMAD4*), cell signaling proteins (*TP53*, *WAS*), and other proteins (*FANCA*, *FANCC*) are linked to impaired hematopoiesis, causing thrombocytopenia of varying severity with evidence for concomitant platelet function defects ([Table 1](#t1-1052020){ref-type="table"} and [Figure 1](#f1-1052020){ref-type="fig"}).

ETV6
----

The transcriptional repressor *E26 transformation-specific variant 6* (ETV6) serves to maintain the development of hematopoietic stem cells in the BM as a continuous survival signal. It acts by inhibiting other transcription factors, such as FLI1. However, it appears not to be required for embryonic stem cell expansion.^[@b46-1052020]^

*ETV6* is known as a proto-oncogene, since it can be a fusion partner with over 30 other genes, but in case of truncating mutations it acts as a tumor suppressor gene. Depending on the fusion site, the fused protein can alter the transcription levels of ETV6 target genes, which may support the development of leukemia.^[@b46-1052020],[@b47-1052020]^ On the other hand, germline heterozygous *ETV6* mutations have been identified in some patients with dominantly inherited thrombocytopenia.^[@b48-1052020]^ Such patients seem to have a predisposition to hematologic malignancies, most commonly ALL, AML or MDS. Given that the complete loss of *ETV6* is lethal, truncating or protein-inactivating mutations are mainly found as somatic events, and rarely as germline variants.^[@b46-1052020]^

As a transcriptional repressor, ETV6 has an established role in megakaryocyte and platelet (patho)physiology. Patients with germline *ETV6* variants show a large expansion of immature megakaryocyte colony-forming units, accompanied by a reduced formation of proplatelets, thus explaining the thrombocytopenia. The mutant platelets are of normal size, although characterized by aberrant cytoskeleton organization, lower levels of small GTPases, and defective clot retraction.^[@b49-1052020]^ Evidence is lacking to link clonal variants of *ETV6* to thrombotic phenotypes; however, a related bleeding tendency has been described.

FANCA, FANCC
------------

The proteins *Fanconi anemia complementation group A and C* (FANCA/C) are repair factors after DNA damage or apoptosis. Inherited mutations in either gene are seen in the disorder Fanconi anemia, where patients in 60-70% of the cases show a mutation in *FANCA* and in 15% a mutation in *FANCC*. Such patients suffer from progressive bone marrow failure, pancytopenia and predisposition to cancer.^[@b50-1052020]^ Knockout mouse studies revealed that FANCA is needed for normal megakaryopoiesis and platelet production. Megakaryocytes in the deficient mice were found to be in a senescent state.^[@b50-1052020]^

In humans, heterozygous mutations of *FANCA* are observed in a proportion of patients with AML.^[@b51-1052020]^ However, carriers of such mutations do not seem to have a significant risk of developing cancer.^[@b52-1052020]^ On the other hand, *FANCA* deletion mutations, especially in combination with other germline mutations, might contribute to breast cancer susceptibility.^[@b53-1052020]^ The phenotype coupled to somatic mutations in *FANCA* and/or *FANCC* is probably linked to genomic instability caused by defective FANC proteins.^[@b51-1052020]^ How these somatic mutations contribute to CHIP-related CVD needs to be established.

GATA2
-----

In immature hematopoietic stem cells, the transcription factor *GATA-binding factor 2* (GATA2) is expressed earlier than GATA1, and becomes down-regulated upon differentiation.^[@b54-1052020]^ This has also been observed in *Gata2*-knockout mice, revealing that GATA2 is required for hematopoietic stem cell and progenitor cell development.^[@b55-1052020]^ In humans, congenital GATA2 deficiency is accompanied by a hypocellular and dysplastic bone marrow, resulting in low platelet counts.^[@b55-1052020]^ Furthermore, germline deletion mutations in the *GATA2* gene are associated with an increased predisposition to infection, AML, CMML or MDS.

On the other hand, a somatic mutation (L359V) in *GATA2* has been identified in approximately 10% of patients in the progression phase of CML.^[@b56-1052020]^ This concerns a gain-of-function resulting in increased transcription factor activity, in contrast to gene deletion. Reports indicate that in approximately 50% of patients with any *GATA2* mutation, the megakaryocyte development is abnormal.^[@b57-1052020]^ Unlike GATA1, GATA2 regulates platelet GPIIb rather than GPIb expression.^[@b54-1052020]^ Variants of *GATA2* have also been associated with increased susceptibility for coronary artery disease,^[@b58-1052020]^ linking this gene to CHIP.

GFI1B
-----

Another transcription regulator crucial for erythroid and megakaryocytic differentiation is *growth factor independent 1B transcription repressor* (GFI1B). As a DNA-binding protein, it regulates the dormancy and mobilization of hematopoietic stem cells.^[@b59-1052020]^ Next to the full-size protein of 330 amino acids implicated in megakaryopoiesis, a shorter form is expressed that may rather regulate erythroid development.^[@b60-1052020]^ The longer protein modulates the expression of several proto-oncogenes and tumor suppressor genes.^[@b59-1052020]^ Accordingly, a functional disturbance of GFI1B can contribute to leukemia development. In mice, genetic deletion of *Gfi1b* resulted in early lethality, where the embryos showed failed megakaryocyte development.^[@b61-1052020]^

For human *GFI1B*, both germline and somatic mutations have been identified. These generally result in a truncated or a dysfunctional form of the protein, thereby reducing DNA binding and transcription repressor activity.^[@b62-1052020]^ In the inherited disorder gray platelet syndrome, patients with a *GFI1B* mutation display (macro)thrombocytopenia with platelets that are reduced in α-granules.^[@b63-1052020]^ The patient's platelets were also found to be reduced in GPIb and GPIIb/IIIa expression, whereas that of the hematopoietic precursor marker CD34 was markedly increased. The suggestion that, in these and other patients with a truncating mutation of *GFI1B*, megakaryocyte development is impaired was recently supported by platelet proteome analysis.^[@b64-1052020]^ In mice, a megakaryocyte-specific deletion of *Gfi1b* enhanced the expansion of megakaryocytes, but resulted in severe thrombocytopenia.^[@b65-1052020]^ Here, the (tubulin) cytoskeleton appeared to be underdeveloped in the mutant megakaryocytes, explaining an inadequate proplatelet formation.

Whole-exome sequencing efforts have revealed the presence of alternative *GFI1B* splice variants, which is accompanied by impaired megakaryocyte differentiation and thrombopoiesis.^[@b60-1052020]^ However, in heterozygous carriers, platelet counts and function were in normal ranges. Little is known about clonal hematopoiesis. A somatic mutation of *GFI1B* has been identified in patients with AML.^[@b59-1052020]^

SMAD4
-----

The 'vascular' transcription factor *SMAD family member 4* (SMAD4) acts as a tumor suppressor, triggered by signaling pathways evoked by transforming growth factor-β or bone morphogenetic protein.^[@b66-1052020]^ Within the cellular nucleus, SMAD4 forms a complex with other SMAD isoforms to control gene expression. In mice, SMAD4 was found to play a role especially in vascular development.^[@b66-1052020]^ On the other hand, a megakaryocyte-specific deficiency of SMAD4 is described, causing mild thrombocytopenia with partially dysfunctioning platelets, likely as a consequence of altered promotor activities.^[@b67-1052020]^

In humans, both somatic and inherited mutations of *SMAD4* are known. Inherited mutations of the gene present with distinct phenotypes, ranging from a vascular bleeding disorder (hereditary hemorrhagic telangiectasia) to gastro-intestinal and bone marrow abnormalities.^[@b68-1052020]^ Somatic mutations of the 358-515 amino-acid region are linked to pancreatic carcinoma.^[@b69-1052020]^ During the screening for somatic driver mutations linked to clonal hematopoiesis, a similar mutation of *SMAD4* was found.^[@b16-1052020]^ Mutations in *SMAD4* are related to a bleeding rather than thrombotic phenotype.

TP53
----

The tumor suppressor *tumor protein p53* (TP53 or p53) is a critical player in cell cycle progression and apoptosis. Herein, TP53 maintains the quiescent state of hematopoietic stem cells, and controls DNA damage responses upon cellular stress.^[@b70-1052020]^ In megakaryocytic cells derived from *Tp53* knockout mice, cell size and polyploidization were increased due to higher DNA synthesis and decreased apoptosis. In human cell cultures, *TP53* knockdown affected the expression of platelet integrins, granule components and cytoskeletal proteins, which was accompanied by functional platelet defects.^[@b71-1052020]^

Regarding human disease, the *TP53* deletion occurring in multiple myeloma is accompanied by a lowering in platelet count.^[@b72-1052020]^ In this context, mutant *TP53* forms are considered to drive clonal hematopoiesis *via* the epigenetic regulator EZH2, leading to overmethylation of histone H3. This can down-regulated several genes associated with self-renewal and differentiation of hematopoietic stem cells.^[@b70-1052020]^ A common consequence is expansion of the affected hematopoietic cell clones. Markedly, the *TP53* gene is top ranking in mutated genes found in CHIP.^[@b73-1052020]^ How mutated *TP53* in hematopoietic cells contributes to CHIP-associated CVD still remains to be determined. Few studies have shown that there is higher expression of pro-inflammatory cytokines in *p53*-deficient murine leukocytes, which may accelerate the development of CVD.^[@b9-1052020]^ However, there is no evidence directly linking platelet traits to CVD development.

WAS
---

The *Wiskott-Aldrich syndrome* (WAS) protein is selectively expressed in hematopoietic cells, where it regulates actin cytoskeleton rearrangements. In the classical X-linked Wiskott-Aldrich syndrome, patients suffer from thrombocytopenia with smaller sized platelets and recurrent infections, due to an impaired functionality or availability of WAS.^[@b74-1052020]^ A milder phenotype is that of X-linked thrombocytopenia, in which patients only suffer from bleeding because of low platelet count.^[@b74-1052020]^ Rare inherited mutations that instead cause constitutive WAS activation are seen in patients with X-linked neutropenia, experiencing recurrent bacterial infections while having normal platelet count and size.^[@b75-1052020]^ In addition, these patients show an increased predisposition for AML or MDS.^[@b76-1052020]^

In classical Wiskott-Aldrich syndrome patients, the prevalence of malignancy is 13-22%, mostly due to development of lymphoma, but also to lymphoblastic leukemia, MDS or MPD.^[@b76-1052020]^ The thrombocytopenia is likely caused by increased platelet removal. In *Was*-deficient mice, platelet turnover was shortened, with proteomic evidence for alterations in proteins of metabolic and proteasomal pathways.^[@b77-1052020]^ Furthermore, in both the mutant mice and patients, there is evidence for a hyperactivation status of the platelets, thus explaining the higher elimination rate. Several groups reported on alterations in integrin activation in the patient's platelets.^[@b78-1052020],[@b79-1052020]^ However, one patient study concluded platelet activation properties were normal.^[@b80-1052020]^

There is limited evidence for the presence of somatic mutations in the *WAS* gene. This mainly concerns gain-of-function mutations, associated with poor outcome in patients with juvenile myelomonocytic leukemia.^[@b81-1052020]^ This suggested a clonal role of the gene in the pre-malignant state.

Section 3: Clonal mutations in other genes
==========================================

For the genes *FLI1* and *GATA1* encoding for transcription regulators, whether the mutation is gain-of-function or loss-of-function likely determines its respective effect on platelet count and/or function. Mutations in *TET2* have been associated with increased inflammation-induced atherosclerosis and thrombotic disease, although possible effects on platelets remain to be established ([Table 1](#t1-1052020){ref-type="table"} and [Figure 1](#f1-1052020){ref-type="fig"}).

FLI1
----

The protein *Friend leukemia virus integration 1* (FLI1) is a member of the ETS transcription factor family, which is highly expressed in the hematopoietic lineage and endothelial cells. Due to a faulty vasculature, *Fli1* knockout mice die during embryonic development, but heterozygous mice are viable without apparent phenotype.^[@b82-1052020]^ Detailed studies indicate that FLI1 plays an important role in both erythropoiesis and megakaryopoiesis by regulating the expression of multiple genes.^[@b83-1052020]^ It acts together with the transcription factor GABPA, especially in later phases of megakaryopoiesis. This is exemplified by the fact that, in *Fli1* knockout mice, megakaryocytes are specifically reduced in the expression of late-stage genes, e.g. genes encoding for glycoprotein (GP)Ibα, GPIX and platelet factor 4.^[@b82-1052020]^

In humans, heterozygous mutations in *FLI1* are commonly grouped together as 'Bleeding disorder platelet-type 21' (Phenotype MIM 617443). Examples are the Jacobsen syndrome and Paris-Trousseau syndrome, which are characterized by a heterozygous partial deletion of chromosome 11, encompassing the *FLI1* gene. Such patients characteristically suffer from abnormal growth and mental retardation, accompanied by thrombocytopenia, most likely due to impaired megakaryopoiesis.^[@b84-1052020]^ In the Paris-Trousseau syndrome, platelets are enlarged and contain large fused α-granules.^[@b84-1052020]^ In patients with a mutated *FLI1* gene, presenting with congenital macrothrombocytopenia, also an impaired agonist-induced platelet aggregation has been reported.^[@b85-1052020]^

In the case of somatic mutations, *FLI1* can become fusion partner with the transcriptional repressing gene *EWSR1*, a condition known as Ewing sarcoma.^[@b86-1052020]^ The effect on platelets is unclear. On the other hand, *in vitro* studies have indicated that the overexpression of *FLI1* in stem cells enhances megakaryopoiesis, thrombopoiesis, and platelet functionality.^[@b87-1052020]^ Furthermore, deregulated high levels of FLI1 are found in various types of cancer. In agreement with this, a predisposition to pre-T-cell lymphoblastic leukemia and lymphoma is described for transgenic mice over-expressing *Fli1* in the hematopoietic progenitor cells.^[@b83-1052020]^ It remains to be established whether *FLI1* is a main contributing gene in CHIP-related CVD.

GATA1
-----

The transcription factor *GATA-binding protein 1* (GATA1) controls the development and production of megakaryocytes, platelets and erythrocytes. In mouse studies, the loss of *Gata1* in the megakaryocyte lineage resulted in smaller size megakaryocytes and a defect in proplatelet formation. The *Gata1*-deficient platelets were larger in size, showed an excess in rough endoplasmic reticulum, and contained fewer α-granules.^[@b88-1052020]^ Furthermore, the deficient mice were impaired in red blood cell development, and often died because of anemia.^[@b89-1052020]^ Consistent with this, *GATA1* is highly expressed in human megakaryocytes and erythroid cells. Mutations in *GATA1* can appear as germline or somatic. Inherited mutations associate with hematopoietic disorders, characterized by low blood cell counts. On the other hand, somatic mutations often result in the production of shorter GATA1 variants, for example, in cases of AMKL (acute megakaryoblastic leukemia) or Down syndrome.^[@b54-1052020]^ Here, platelets tend to be low in counts and display an atypical morphology.

A common consequence of germline *GATA1* mutations in hematopoietic disorders is the altered interaction of GATA1 with its co-factor FOG1, i.e. a zinc finger protein co-operating with GATA1 to regulate cell differentiation. This has been reported for patients with X-linked thrombocytopenia, or other forms of macrothrombocytopenia, who experience bleeding diatheses.^[@b90-1052020]^ The patient's megakaryocytes are abnormal in structure and the platelets show decreased numbers of α-granules.^[@b90-1052020]^ Patients with primary myelofibrosis, having upstream driver mutations resulting in low GATA1 levels in megakaryocytes, show an increased risk of both thrombosis and bleeding. Mice with *Gata1*^low^ mutation resemble this phenotype, demonstrating similar megakaryocyte abnormalities, such as abnormal P-selectin localization, and thrombo-hemorrhagic events. The prothrombotic state was ascribed to increased platelet-leukocyte interactions through P-selectin.^[@b91-1052020]^

In cultured megakaryocytes, GATA1 has been shown to regulate the expression of GPIIb (fibrinogen receptor) and GPIb (von Willebrand factor receptor). Markedly, in *GATA1*-deficient megakaryocytes, expression levels of GPIIb can be maintained by GATA2 substitution, whereas those of GPIb are decreased.^[@b54-1052020]^ As expected, inherited mutations of *GATA1* are accompanied by a bleeding phenotype rather than by an increased risk of thrombosis. On the other hand, high levels of *GATA1* transcripts are found in patients with ET or PV.^[@b92-1052020]^ Overexpression of *GATA1* in mice results in a similar phenotype.^[@b93-1052020]^ Regarding CHIP, somatic gain-of-function may increase the cardiovascular risk including atherothrombosis, whereas loss-of-function may be more associated with bleeding.

TET2
----

The protein *Tet oncogene family member 2* (TET2) has a key role in DNA methylation, explaining how it functions as a tumor suppressor, maintaining normal hematopoiesis. The *TET* gene product in particular represses the transcription of inflammatory molecules, such as interleukin-6 and -8, which are known as proatherogenic mediators.^[@b1-1052020],[@b94-1052020]^ This explains why somatic loss-of-function mutations in *TET2* are associated with an increased inflammation tendency. Similarly, as described for *DNMT3A*, the mutations may increase the burden of atherosclerosis and arterial CVD.

Murine *Tet2*-null models are used to confirm that CHIP-like mutations lead to inflammation-driven cardiovascular pathologies,^[@b7-1052020],[@b95-1052020]^ markedly without changes in blood cell counts. In the aging population, clonal hematopoietic mutations of *TET2* have a prevalence of 2.5%.^[@b16-1052020]^ On the other hand, such mutations are found in approximately 25% of patients with myeloid neoplasms, and are then associated with an increased cardiovascular risk.^[@b7-1052020]^ It is still not clear to what extent the mutations affect megakaryopoiesis or platelet function, either directly or indirectly *via* enhanced inflammation.

Conclusions and perspectives
============================

As outlined above, somatic mutations in multiple genes affecting hematopoiesis contribute as a risk factor to the development of CVD. So far, studies have focused on the effects of somatic and CHIP-linked mutations on blood cells, linking to increased inflammation, atherosclerotic disease and thrombosis risk. In this review, we provide evidence that many of the common CHIP genes are involved in quantitative (count) and/or qualitative (function) platelet traits, and therefore in this way can influence CVD, in particular triggered by thrombo-inflammatory mechanisms. On the other hand, insight is gained in a link between mutations in CHIP genes and impairment of hematopoiesis and hemostatic function.

Reactive (secondary) thrombocytosis, which is not due to a primary hematologic disorder but driven by inflammatory stimuli, trauma or acute bleeding, does not seem to increase the risk of thrombotic or hemorrhagic complications.^[@b96-1052020]^ In line with this, the degree of elevation in the platelet count does not correlate with the thrombosis risk in myeloproliferative disease, where clonal (primary) thrombocytosis has been demonstrated.^[@b97-1052020]^ This indicates that the platelet count as such is not the only determinant of the increased thrombosis risk in myeloproliferative disorders.^[@b98-1052020],[@b99-1052020]^ Also, several CHIP mutations (e.g. *DNMT3A* mutations) can indirectly cause a rise in platelet count by inducing increased expression of inflammatory molecules that subsequently upregulate the thrombopoietin production by the liver. However, the combination of alterations in count and function may play an essential role in CHIP mutations related to thrombosis. So far, we have found evidence of seven CHIP-related genes (*ABCB6*, *ASXL1*, *DNMT3A*, *GATA1*, *JAK2*, *SF3B1*, *SH2B3*) with elevated platelet counts and an associated thrombotic risk ([Figure 1](#f1-1052020){ref-type="fig"}). For the other genes, there is not enough evidence to make estimates of this kind; only for *ABCB6*, *JAK2* and *SH2B3* mutations is it known that the elevated platelet count is accompanied by a hyper-reactive platelet phenotype. Apparently, information regarding the functional status of platelets in the context of CHIP mutations is still scarce and further studies are needed to elucidate the contribution of platelets to the risk of thrombosis.

One of the most thoroughly investigated conditions, demonstrating the consequences of altered platelet traits due to somatic driver mutations, is essential thrombocythemia. Markedly, in these patients, there appears to be no direct correlation between platelet count and thrombosis. On the other hand, the *JAK2* V617F mutation is known to increase the thrombosis risk in ET patients, when compared to patients without the mutation.^[@b100-1052020]^ The reported enhanced activation status of platelets in *JAK2* V617F-positive patients provides a strong indication that platelet function changes induced by a CHIP mutation contribute to the risk of thrombosis, thus explaining part of the risk associations of CHIP mutations with CVD. Platelet reactivity also involves interactions with leukocytes, secretion of pro-inflammatory mediators and release of extracellular vesicles that may all contribute to CVD, like atherosclerosis and atherothrombosis. Given the increasing prevalence of CHIP mutations in the elderly who are prone to develop CVD (along with malignancies), more thorough investigation of platelet function linked to CHIP mutations would be worthwhile. Greater insight into the functional consequences of such acquired mutations may also favor personalized risk assessment, not only with regard to malignancies, but also in relation to thrombotic vascular disease.
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